3M India Q2 FY27 Results: Standalone Net Profit ₹158 Crore on Total Income of ₹1,464 Crore
- Earnings
- Diversified industrial products
Reviewed byKeshav SehgalBlacklitt Research
3M India (NSE: 3MINDIA) reported total income of ₹1,463.66 crore and net profit of ₹158.48 crore on a standalone basis for the quarter ended 30 Sep 2026.
Key highlights
Standalone
The company on its own, without its subsidiaries
- Total income: ₹1,463.66 crore, up 14.5% YoY and 2.0% QoQ
- Net profit and EPS: ₹158.48 crore, down 17.2% YoY; basic EPS ₹140.68
- Exceptional item: ₹73.13 crore gain on Pimpri land sale in the quarter ended 30 Jun 2026; nil in this quarter
- Dividend paid: ₹506 per share for FY 2025-26: final ₹160 and special ₹346
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 1,463.66 | 1,278.81 | +14.5% | 1,434.85 | +2.0% | |
| Revenue from operations | 1,452.49 | 1,266.49 | +14.7% | 1,423.21 | +2.1% |
| Other income | 11.17 | 12.32 | -9.3% | 11.64 | -4.0% |
| 158.48 | 191.34 | -17.2% | 233.07 | -32.0% | |
| Profit before tax | 212.32 | 250.81 | -15.3% | 302.16 | -29.7% |
| Finance costs | 4.27 | 2.32 | +84.1% | 3.98 | +7.3% |
| Depreciation | 17.61 | 15.04 | +17.1% | 16.68 | +5.6% |
| Tax expense | 53.84 | 59.47 | -9.5% | 69.09 | -22.1% |
| Net profit margin | 10.83% | 14.96% | -4.13 pp | 16.24% | -5.42 pp |
| EPS, basic (₹) | 140.68 | 169.85 | -17.2% | 206.90 | -32.0% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Net profit fell 17.2% to ₹158.48 crore while total income rose 14.5% to ₹1,463.66 crore. Revenue from operations grew 14.7%, and other income fell 9.3% to ₹11.17 crore, which is 0.8% of total income and 5.3% of profit before tax of ₹212.32 crore. Profit before tax fell 15.3%, a little less than the fall in net profit.
Tax expense of ₹53.84 crore is 25.4% of profit before tax, against ₹59.47 crore a year earlier on ₹250.81 crore. Finance costs rose from ₹2.32 crore to ₹4.27 crore, still 0.3% of total income, and depreciation rose 17.1% to ₹17.61 crore. The company says the fall in profit after tax is primarily due to Indian Rupee depreciation and input cost inflation due to the Middle East crisis.
Against the prior quarter, revenue rose 2.1% while net profit fell 32.0%. The quarter ended 30 Jun 2026 carried a ₹73.13 crore exceptional gain on the Pimpri land sale, which the filing shows in that quarter and in the six months to 30 Sep 2026; the quarter ended 30 Sep 2026 has no exceptional item.
Inference
The filing records a dividend of ₹506 per equity share for FY 2025-26, paid in the quarter ended 30 Sep 2026: a final dividend of ₹160 and a special dividend of ₹346, approved at the AGM on 26 Aug 2026. On the share count implied by paid-up capital of ₹11.27 crore, the payout is about ₹570.26 crore.
On 26 Oct 2026 the Board approved key commercial terms for amendments to healthcare agreements, under which the company is to receive a one-time compensation of US$13 million from Thermo Fisher Scientific Inc. and/or its nominated affiliate, subject to agreed conditions. The company has treated this as a non-adjusting event and made no adjustment to the results. The filing does not say when the compensation will be received or how it will be recognised.
Mr. Chun Hao Lok was appointed an additional director, non-executive and non-independent, effective 7 Nov 2026, subject to shareholder approval by postal ballot. Ms. Kong Sau Wai Elizabeth resigned from the board effective 6 Nov 2026 to pursue professional opportunities outside 3M, and the committees were reconstructed effective 7 Nov 2026. The filing does not say who will replace her on the committees.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
